The first sign of trouble came when the European Medicines Agency (EMA) and the World Health Organization (WHO) initially failed to acknowledge that there could be any potential links between AstraZeneca's vaccine and blood clotting. When several European countries, including Germany, France, and Italy, suspended the vaccine due to safety concerns, AstraZeneca's response was slow, defensive, and insufficient.